Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mitry

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Oncogene|August 30, 2001
No evidence of somatic FGFR3 mutation in various types of carcinomaM Karoui, H Hofmann-Radvanyi, U Zimmermann, et al.
Translational Oncology|December 15, 2021
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancerR Nicolle, O Gayet, M Bigonnet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)T Aparicio, S Lavau-Denes, J M Phelip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2024
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinomaN Fraunhoffer, P Hammel, T Conroy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panelJ-L Van Laethem, C Verslype, J L Iovanna, et al.
British Journal of Cancer|April 26, 2014
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialC Le Tourneau, X Paoletti, N Servant, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Oncogene|August 30, 2001
No evidence of somatic FGFR3 mutation in various types of carcinomaM Karoui, H Hofmann-Radvanyi, U Zimmermann, et al.
Translational Oncology|December 15, 2021
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancerR Nicolle, O Gayet, M Bigonnet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)T Aparicio, S Lavau-Denes, J M Phelip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2024
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinomaN Fraunhoffer, P Hammel, T Conroy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panelJ-L Van Laethem, C Verslype, J L Iovanna, et al.
British Journal of Cancer|April 26, 2014
Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialC Le Tourneau, X Paoletti, N Servant, et al.
Pageof 6